CBIO Q3 2018 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$68,477

Operating Income

-$13M

Net Income

-$12M

EPS (Diluted)

$-0.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$225M

Total Liabilities

$7M

Stockholders' Equity

$218M

Cash & Equivalents

$220M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$68,477	-$70,060	+2.3%
Operating Income	-$13M	-$8M	-53.0%
Net Income	-$12M	-$8M	-45.6%